test

Flynn Management LLC, its general partner

@Deerfield Management Company, L.p. (series C)

Latest period2024 - Q3ReportedManaged Assets$6.693BTotal holdings443
Assets growth rate11.36%Assets growth rate (2-Q avg)7.96%Continuous growth in asset value4 quarters

Portfolio positions

This chart displays the top 10 holdings in Deerfield Management Company, L.p. (series C)'s 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 443 positions.

Assets under management

The assets under management (AUM) of Deerfield Management Company, L.p. (series C) over the past 10 years (40 quarters) show continuous growth in total asset value over the last 4 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 6.693B in assets, with a quarterly growth rate of 11.36% and a 2-quarter average growth rate of 7.96%. The portfolio is managed by Flynn Management LLC, its general partner, and others.

Portfolio holdings

CurrentNew PositionIncreasedDecreasedExited
InvestmentPortfolio %Reported Value
4576⤦Insmed Inc
Recent Activity
Exited
0%
$258.672M
151.408M shares@ $1.71 avg price
1124⤦Brookdale Sr Living Inc
Recent Activity
Exited
0%
$163.298M
161.905M shares@ $1.01 avg price
GILDGilead Sciences Inc
Recent Activity
Exited
0%
$102.298M
1.491M shares@ $68.61 avg price
IARTIntegra Lifesciences Hldgs C
Recent Activity
Exited
0%
$42.767M
1.468M shares@ $29.14 avg price
APGEApogee Therapeutics Inc
Recent Activity
Exited
0%
$12.946M
329,000 shares@ $39.35 avg price
ITOSIteos Therapeutics Inc
Recent Activity
Exited
0%
$10.729M
723,000 shares@ $14.84 avg price
SLDBSolid Biosciences Inc
Recent Activity
Exited
0%
$9.885M
1.743M shares@ $5.68 avg price
EYPTEyepoint Pharmaceuticals Inc
Recent Activity
Exited
0%
$7.637M
877,790 shares@ $8.7 avg price
6404⤦Neogenomics Inc
Recent Activity
Exited
0%
$6.306M
6.5M shares@ $0.98 avg price
GUTSFractyl Health Inc
Recent Activity
Exited
0%
$3.562M
834,254 shares@ $4.28 avg price